Navigating Renin-Angiotensin System Inhibitors in Patients with Declines in eGFR.
作者信息
Shulman Rachel, Cohen Jordana B
机构信息
Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
J Am Soc Nephrol. 2024 Oct 1;35(10):1309-1311. doi: 10.1681/ASN.0000000000000470. Epub 2024 Aug 13.
Abstract
摘要
相似文献
1
Navigating Renin-Angiotensin System Inhibitors in Patients with Declines in eGFR.肾小球滤过率下降患者中肾素-血管紧张素系统抑制剂的应用指导
J Am Soc Nephrol. 2024 Oct 1;35(10):1309-1311. doi: 10.1681/ASN.0000000000000470. Epub 2024 Aug 13.
2
Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.肾素-血管紧张素-醛固酮系统的抑制：如何实现这一点。
Curr Pharm Des. 2012;18(7):950-1. doi: 10.2174/138161212799436494.
3
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
4
How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?面对心肾综合征时，我们应如何调整推荐的肾素-血管紧张素-醛固酮系统抑制治疗？
Circ Heart Fail. 2014 May;7(3):536. doi: 10.1161/CIRCHEARTFAILURE.113.000843.
5
Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.在慢性肾病患者中，添加维生素D可逆转使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂治疗后肾小球滤过率的下降。
Life Sci. 2017 Dec 15;191:175-179. doi: 10.1016/j.lfs.2017.10.028.
6
Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.肾素-血管紧张素系统抑制在晚期慢性肾脏病中的应用。
N Engl J Med. 2022 Dec 1;387(22):2021-2032. doi: 10.1056/NEJMoa2210639. Epub 2022 Nov 3.
7
Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?肾素-血管紧张素系统阻断在晚期慢性肾脏病中的作用：用还是不用？
Hypertens Res. 2022 Jun;45(6):1072-1075. doi: 10.1038/s41440-022-00902-7. Epub 2022 Mar 31.
8
Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes.肾素-血管紧张素系统抑制期间估算肾小球滤过率急性下降与不良结局风险之间的关联
J Am Soc Nephrol. 2024 Oct 1;35(10):1402-1411. doi: 10.1681/ASN.0000000000000426. Epub 2024 Jun 18.
9
Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker use and renal outcomes-reply.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的使用与肾脏结局——回复
JAMA Intern Med. 2014 Oct;174(10):1706-7. doi: 10.1001/jamainternmed.2014.1578.
10
The authors reply.
Kidney Int. 2014 Oct;86(4):855. doi: 10.1038/ki.2014.172.
引用本文的文献
1
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025.11. 慢性肾脏病与风险管理：2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S239-S251. doi: 10.2337/dc25-S011.
本文引用的文献
1
Estimated Effect of Restarting Renin-Angiotensin System Inhibitors after Discontinuation on Kidney Outcomes and Mortality.停止使用肾素-血管紧张素系统抑制剂后重新使用对肾脏结局和死亡率的估计影响。
J Am Soc Nephrol. 2024 Oct 1;35(10):1391-1401. doi: 10.1681/ASN.0000000000000425. Epub 2024 Jun 18.
2
Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes.肾素-血管紧张素系统抑制期间估算肾小球滤过率急性下降与不良结局风险之间的关联
J Am Soc Nephrol. 2024 Oct 1;35(10):1402-1411. doi: 10.1681/ASN.0000000000000426. Epub 2024 Jun 18.
3
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
4
Association between stopping renin-angiotensin system inhibitors immediately before hemodialysis initiation and subsequent cardiovascular events.在开始血液透析前立即停止肾素-血管紧张素系统抑制剂与随后发生的心血管事件之间的关联。
Hypertens Res. 2024 May;47(5):1372-1379. doi: 10.1038/s41440-024-01616-8. Epub 2024 Mar 4.
5
Target Trial Emulation: A Framework for Causal Inference From Observational Data.目标试验模拟：一种从观察性数据进行因果推断的框架。
JAMA. 2022 Dec 27;328(24):2446-2447. doi: 10.1001/jama.2022.21383.
6
Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.肾素-血管紧张素系统抑制在晚期慢性肾脏病中的应用。
N Engl J Med. 2022 Dec 1;387(22):2021-2032. doi: 10.1056/NEJMoa2210639. Epub 2022 Nov 3.
7
Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.高钾血症相关的肾素-血管紧张素-醛固酮系统抑制剂停药与 CKD 临床结局的相关性：一项基于人群的队列研究。
Am J Kidney Dis. 2022 Aug;80(2):164-173.e1. doi: 10.1053/j.ajkd.2022.01.002. Epub 2022 Jan 25.
8
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.KDIGO 2021慢性肾脏病血压管理临床实践指南执行摘要。
Kidney Int. 2021 Mar;99(3):559-569. doi: 10.1016/j.kint.2020.10.026.
9
Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.在伴有晚期 CKD 风险的患者中停用肾素-血管紧张素系统抑制剂：一项全国性研究。
J Am Soc Nephrol. 2021 Feb;32(2):424-435. doi: 10.1681/ASN.2020050682. Epub 2020 Dec 28.
10
Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study.肾素-血管紧张素系统阻断后血清肌酐升高与长期心肾风险：队列研究
BMJ. 2017 Mar 9;356:j791. doi: 10.1136/bmj.j791.
Zotero 插件